MAPT and dementia: Secondary outcomes included time to progression to MCI or dementia due to AD, time to a CDR >0, change of CDR-SB, and change in amyloid-PET, cerebral glucose metabolism (FDG PET), volumetric MRI, CSF levels of Aβ, and total and p-tau.